Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.com
Thursday, 10 January 2019 04:06
Jan. 10, 2019 13:47 UTC

Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Global Cardiomyopathy Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.

Advent of genomic medicine to push market growth during the forecast period

Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual.

Initiative to increase awareness about disease

There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.

High cost of treatment

Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.

Key Players

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Dilated cardiomyopathy - Market size and forecast 2018-2023
  • Hypertrophic cardiomyopathy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY PRODUCT

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/t8vxmp/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter